profit from every $100 of sales.
$0$100
Natera
$322.94+0.98% today
+54.1% in 1 year
1-year low $182.651-year high $436.00
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Natera sold, what it kept, and what it did with the cash.
Sales went from $820 million in 2022 to $2.31 billion in 2025, with -$208 million of profit last year.
SalesProfit
Natera vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Natera | No profit yet | ||
 Thermo Fisher Scientific | 38.7× · Expensive | ||
 Danaher | 45.2× · Expensive | ||
 Waters | 141.4× · Very expensive | ||
 WuXi AppTec | 27.1× · Fair price |
Compare Natera with Quest Diagnostics · Labcorp Holdings · Eli Lilly
AI analysis
An AI analyst reads Natera's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 391 | 625 | 820 | 1,083 | 1,697 | 2,306 | |
| – | – | 364 | 493 | 1,023 | 1,493 | |
| -216 | -468 | -541 | -446 | -222 | -310 | |
| -206 | -452 | -521 | -398 | -148 | -221 | |
| -230 | -472 | -548 | -435 | -190 | -208 | |
| -2.84 | -5.21 | -5.57 | -3.78 | -1.53 | -1.52 | |
| – | – | 44.4% | 45.5% | 60.3% | 64.7% | |
| -55.3% | -74.8% | -66.0% | -41.2% | -13.1% | -13.4% | |
| -58.8% | -75.4% | -66.8% | -40.2% | -11.2% | -9.0% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 932 | 1,236 | 1,394 | 1,442 | 1,661 | 2,398 |
| Cash | 49 | 84 | 466 | 642 | 946 | 1,076 |
| Total debt | – | 397 | 446 | 442 | 187 | 214 |
| Total liabilities | 446 | 583 | 689 | 676 | 465 | 686 |
| 486 | 653 | 706 | 765 | 1,195 | 1,712 | |
| 81 | 91 | 98 | 115 | 125 | 137 | |
| -34.9% | -34.8% | -36.9% | -27.6% | -10.2% | -10.8% | |
| -47.2% | -72.2% | -77.6% | -56.8% | -15.9% | -12.2% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -183 | -335 | -432 | -247 | 136 | 215 | |
| – | – | 48 | 39 | 77 | 139 | |
| – | – | -479 | -286 | 59 | 76 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 50 | 115 | 152 | 192 | 274 | 354 |
Valuation
- –
- –
- –
- 30.6×
- 20.3×
- 615.2×
- –
- 0.2%
- -0.4%
- 0.0%
Profitability
- 64.7%
- -13.4%
- -9.0%
- -11.0%
- -11.1%
- -21.9%
- -15.1%
- -8.7%
- -15.8%
- 28.2%
Growth
- +42.6%
- –
- +57.6%
- –
- +11.6%
Financial health
- -3.9×
- 0.13
- 9.2%
- -64.9×
- 3.39
- 2.83
- 0.96
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 952
Bottom 13%of 883
Top 13%of 870
Bottom 41%of 985
What analysts expect
- Average price target
- $262.50
- Range
- $205.00 – $285.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.56 | -0.53 | −5.7% |
| Feb 26, 2026 | 0.35 | -0.51 | +168.4% |
| Nov 6, 2025 | -0.64 | -0.39 | −65.9% |
| Aug 7, 2025 | -0.74 | -0.62 | −20.2% |
| May 8, 2025 | -0.50 | -0.64 | +21.9% |
| Feb 27, 2025 | -0.41 | -0.38 | −7.6% |
| Nov 12, 2024 | -0.26 | -0.57 | +54.4% |
| Aug 8, 2024 | -0.30 | -0.69 | +56.5% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
39No pass
Philip Fisher
44No pass
Peter Lynch
70Pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
30No pass
Questions about Natera
Is Natera a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Natera AI analysis
What does Natera do?
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It is in Diagnostics & Research, based in Austin, TX, United States, with 6,135 employees.
Does Natera pay a dividend?
No. Natera does not pay a dividend at the moment.
Is Natera stock halal?
Yes. Natera passes our halal screen: its business is permitted and its debt is 0.5% of its market value, under the 30% limit. How we check
How has Natera stock done over the past year?
Up 54.1% over the past twelve months, to $322.94. It traded between $182.65 and $436.00 and is 25.9% below its high.
Who are Natera's competitors?
The largest listed companies in the same industry are Thermo Fisher Scientific, Danaher, Waters and WuXi AppTec. The peers table on this page compares their profit, growth and price with Natera's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.